TRPC6 and cancer: Among TRP, TRPC6 is to date the only one being implicated in GBM angiogenesis suggesting that specific TRPC6 inhibitors could simultaneously target both cancer progression and vascularization, thereby improving the efficacy of standard (radio-chemotherapy) options.